ReviewInternational journal of molecular sciences2022
The iNKT Cell-Macrophage Axis in Homeostasis and Disease.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The Defect of iNKT Cells Mediates Mitochondrial Dysfunction Through IL-6/STAT3 Signaling to Induce Atrial Inflammation and Fibrosis to Aggravate Postoperative Atrial Fibrillation.Physiological research · 2026Article
- Dynamic regulation and targeted interventions of macrophages in ischemia-reperfusion injury.Journal of advanced research · 2026Review
- Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome.Diabetology & metabolic syndrome · 2025Review
- Review
- Identification and Characterization of Prognostic Macrophage Subpopulations for Human Esophageal Carcinoma.Current medicinal chemistry · 2025Article
- CD1 molecules: Beyond antigen presentation.Molecular immunology · 2024Review
- Motility and tumor infiltration are key aspects of invariant natural killer T cell anti-tumor function.Nature communications · 2024Article
- Protective effects ofFrontiers in pharmacology · 2024Article
- Deficiency and dysfunctional roles of natural killer T cells in patients with ARDS.Frontiers in immunology · 2024Article
- CSF-1R+ Macrophages Control the Gut Microbiome-Enhanced Liver Invariant NKT Function through IL-18.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Natural Killer Cells and Immunotherapy.International journal of molecular sciences · 2023Article
- Leishmaniasis: Immune Cells Crosstalk in Macrophage Polarization.Tropical medicine and infectious disease · 2023Review
- Novel potential therapeutic targets of alopecia areata.Frontiers in immunology · 2023Review
- Human iNKT Cells Modulate Macrophage Survival and Phenotype.Biomedicines · 2022Article
- CD8Frontiers in immunology · 2022Review
- Expansion of iNKT Cells Promotes Liver Repair Following Hepatic Ischemia Reperfusion Injury.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invariant natural killer T (iNKT) cells are CD1d-restricted, lipid-reactive T cells that exhibit preponderant immunomodulatory properties. The ultimate protective or deleterious functions displayed by iNKT cells in tissues are known to be partially shaped by the interactions they establish with other immune cells. In particular, the iNKT cell-macrophage crosstalk has gained growing interest over the past two decades. Accumulating evidence has highlighted that this immune axis plays central roles not only in maintaining homeostasis but also during the development of several pathologies. Hence, this review summarizes the reported features of the iNKT cell-macrophage axis in health and disease. We discuss the pathophysiological significance of this interplay and provide an overview of how both cells communicate with each other to regulate disease onset and progression in the context of infection, obesity, sterile inflammation, cancer and autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.